Aqilion hires Martin Johansson as medicinal chemistry expert

Martin Johansson holds a doctorate in organic chemistry from Lund University, Sweden, where he is currently an Associate Professor at the Center for Analysis and Synthesis. He has almost 20 years’ experience of medicinal chemistry and commercial drug discovery. Martin has previously held positions as senior researcher in AstraZeneca’s organization for Discovery R&D, in Södertälje, […]

Aqilion receives SEK 100 million through conversion of outstanding warrants

In March of 2018, AQILION AB (formerly Partners för Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB) carried out a directed issue of “units.” Each unit consisted of one (1) share and two (2) warrants. At that time, Aqilion raised SEK 100 million through subscription for shares. All outstanding warrants have now been converted to shares, which […]

Aqilion initiates collaboration with Immunscape

Aqilion searches for early innovative pharmaceutical projects thatare based on solid research resting on a firm biological foundation and offering both clinical relevance and patient benefit. Immunscape has developed innovative molecules that could potentially become new drugs for the treatment of cancer and autoimmune diseases. The project is currently in an early phase of development. […]


16 October 2019: EARLY CLINICAL DEVELOPMENT at World Trade Center in Stockholm

Aqilion’s CEO Sarah Fredriksson is giving a presentation on the topic of finding new interesting projects. EARLY CLINICAL DEVELOPMENT on the 16th of October 2019 at World Trade Center in Stockholm Early_clinical_program.pdf  

15 October 2019: Nordic Female Investor Meet

Aqilion will attend the Nordic Female Investor Meet Up on the 15th of October in Malmö. Read more about the NFIM 2019 here:  

Aqilion is a Swedish life science company

We believe the best source of new treatments comes from identifying, shaping and strengthening early drug innovation. We seek ideas that could potentially both improve patient quality of life and streamline health care. 

We want to challenge and apply science in combination with creativity and entrepreneurship to maximize health care value for society. 

The word “Aqilion” derives from Aquila, the Latin for eagle, and from the Aquila constellation, seen in the Nordic sky. The name symbolizes the concept of a constellation of partners, as well as the ability to exercise an “eagle eye” by applying the company’s extensive experience to identify and pursue unique opportunities.

For more info contact us here!

© Copyright 2019 Aqilion AB